317 related articles for article (PubMed ID: 24953538)
1. Informing women with breast cancer about endocrine therapy: effects on knowledge and adherence.
Heisig SR; Shedden-Mora MC; von Blanckenburg P; Schuricht F; Rief W; Albert US; Nestoriuc Y
Psychooncology; 2015 Feb; 24(2):130-7. PubMed ID: 24953538
[TBL] [Abstract][Full Text] [Related]
2. Adherence to Adjuvant Endocrine Therapy in Women With Breast Cancer: A Prospective Observational Study in Japanese Women.
Kuba S; Maeda S; Matsumoto M; Yamanouchi K; Yano H; Morita M; Sakimura C; Hatachi T; Tokai Y; Takatsuki M; Fujioka H; Hayashida N; Nagayasu T; Eguchi S
Clin Breast Cancer; 2018 Apr; 18(2):150-156. PubMed ID: 29290564
[TBL] [Abstract][Full Text] [Related]
3. Excess mortality in postmenopausal high-risk women who only receive adjuvant endocrine therapy for estrogen receptor positive breast cancer.
Ejlertsen B; Jensen MB; Mouridsen HT;
Acta Oncol; 2014 Feb; 53(2):174-85. PubMed ID: 24219541
[TBL] [Abstract][Full Text] [Related]
4. Adherence to adjuvant endocrine therapy in estrogen receptor-positive breast cancer patients with regular follow-up.
Simon R; Latreille J; Matte C; Desjardins P; Bergeron E
Can J Surg; 2014 Feb; 57(1):26-32. PubMed ID: 24461223
[TBL] [Abstract][Full Text] [Related]
5. Selecting adjuvant endocrine therapy for breast cancer.
Eneman JD; Wood ME; Muss HB
Oncology (Williston Park); 2004 Dec; 18(14):1733-44, discussion 1744-5, 1748, 1751-4. PubMed ID: 15700624
[TBL] [Abstract][Full Text] [Related]
6. Adherence to adjuvant endocrine therapy in women with breast cancer.
Danilak M; Chambers CR
J Oncol Pharm Pract; 2013 Jun; 19(2):105-10. PubMed ID: 22895656
[TBL] [Abstract][Full Text] [Related]
7. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
Ellis MJ; Tao Y; Luo J; A'Hern R; Evans DB; Bhatnagar AS; Chaudri Ross HA; von Kameke A; Miller WR; Smith I; Eiermann W; Dowsett M
J Natl Cancer Inst; 2008 Oct; 100(19):1380-8. PubMed ID: 18812550
[TBL] [Abstract][Full Text] [Related]
8. [Adjuvant treatment of breast cancer. Endocrine therapy].
Mouridsen HT; Andersen J
Ugeskr Laeger; 2007 Sep; 169(37):3072-6. PubMed ID: 17877951
[TBL] [Abstract][Full Text] [Related]
9. Which is the appropriate adjuvant endocrine therapy for premenopausal patients with breast cancer?
Petrelli F; Barni S
Clin Breast Cancer; 2015 Jun; 15(3):169-70. PubMed ID: 25600162
[No Abstract] [Full Text] [Related]
10. The impact of educational materials on compliance and persistence rates with adjuvant aromatase inhibitor treatment: first-year results from the compliance of aromatase inhibitors assessment in daily practice through educational approach (CARIATIDE) study.
Neven P; Markopoulos C; Tanner M; Marty M; Kreienberg R; Atkins L; Franquet A; Gnant M; Neciosup S; Tesarova P; Barni S; Deschamp V
Breast; 2014 Aug; 23(4):393-9. PubMed ID: 24675394
[TBL] [Abstract][Full Text] [Related]
11. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.
Coates AS; Keshaviah A; Thürlimann B; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Colleoni M; Láng I; Del Mastro L; Smith I; Chirgwin J; Nogaret JM; Pienkowski T; Wardley A; Jakobsen EH; Price KN; Goldhirsch A
J Clin Oncol; 2007 Feb; 25(5):486-92. PubMed ID: 17200148
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant endocrine therapy for breast cancer.
Rao RD; Cobleigh MA
Oncology (Williston Park); 2012 Jun; 26(6):541-7, 550, 552 passim. PubMed ID: 22870539
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial.
Rasmussen BB; Regan MM; Lykkesfeldt AE; Dell'Orto P; Del Curto B; Henriksen KL; Mastropasqua MG; Price KN; Méry E; Lacroix-Triki M; Braye S; Altermatt HJ; Gelber RD; Castiglione-Gertsch M; Goldhirsch A; Gusterson BA; Thürlimann B; Coates AS; Viale G;
Lancet Oncol; 2008 Jan; 9(1):23-8. PubMed ID: 18083065
[TBL] [Abstract][Full Text] [Related]
14. Persistence and discontinuation of adjuvant endocrine therapy in women with breast cancer.
Kuba S; Ishida M; Nakamura Y; Taguchi K; Ohno S
Breast Cancer; 2016 Jan; 23(1):128-133. PubMed ID: 24934610
[TBL] [Abstract][Full Text] [Related]
15. Adherence and discontinuation of adjuvant hormonal therapy in breast cancer patients: a population-based study.
Wigertz A; Ahlgren J; Holmqvist M; Fornander T; Adolfsson J; Lindman H; Bergkvist L; Lambe M
Breast Cancer Res Treat; 2012 May; 133(1):367-73. PubMed ID: 22286315
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant endocrine therapy for early breast cancer.
Andreetta C; Smith I
Cancer Lett; 2007 Jun; 251(1):17-27. PubMed ID: 17150303
[TBL] [Abstract][Full Text] [Related]
17. Adherence to endocrine therapy for breast cancer.
Chlebowski RT; Geller ML
Oncology; 2006; 71(1-2):1-9. PubMed ID: 17344666
[TBL] [Abstract][Full Text] [Related]
18. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.
; Thürlimann B; Keshaviah A; Coates AS; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Rabaglio M; Smith I; Wardley A; Price KN; Goldhirsch A
N Engl J Med; 2005 Dec; 353(26):2747-57. PubMed ID: 16382061
[TBL] [Abstract][Full Text] [Related]
19. Adherence to long-term adjuvant hormonal therapy for breast cancer.
Gotay C; Dunn J
Expert Rev Pharmacoecon Outcomes Res; 2011 Dec; 11(6):709-15. PubMed ID: 22098287
[TBL] [Abstract][Full Text] [Related]
20. Progress in tailoring adjuvant endocrine therapy for postmenopausal women with early breast cancer.
Bedard PL; Piccart-Gebhart MJ
Curr Opin Oncol; 2009 Nov; 21(6):491-8. PubMed ID: 19593135
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
